CompletedNot Applicable

A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in Korea

South Korea89 participantsStarted 2022-05-10

Plain-language summary

This is a prospective, open-label, multi-center, non-comparative, non-interventional observational study to assess safety and effectiveness of Lutathera in patients with somatostatin receptor-positive GEP-NET in the real-world setting in Korea.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients who start Lutathera treatment per clinical judgment, according to the locally approved labeling.
✓. Patients who are willing to provide written informed consent.

What they're measuring

Incidence of Adverse Events

Timeframe: Up to 36 weeks

Incidence of Adverse Drug Reactions

Timeframe: Up to 36 weeks

Trial details

NCT IDNCT04946305

SponsorNovartis Pharmaceuticals

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2024-07-08

View on ClinicalTrials.gov More Somatostatin Receptor-positive GEP-NET trials